CN1548130A - Medicine for treating coronary heart disease and angina pectoris and its pharmacologic effect - Google Patents
Medicine for treating coronary heart disease and angina pectoris and its pharmacologic effect Download PDFInfo
- Publication number
- CN1548130A CN1548130A CNA031308619A CN03130861A CN1548130A CN 1548130 A CN1548130 A CN 1548130A CN A031308619 A CNA031308619 A CN A031308619A CN 03130861 A CN03130861 A CN 03130861A CN 1548130 A CN1548130 A CN 1548130A
- Authority
- CN
- China
- Prior art keywords
- water
- preparation
- filtrate
- time
- macroporous resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The medicine for treating coronary heart disease and angina pectoris is prepared with red sage as main material, and through water extraction, regulating pH value with acid, filtering, adsorption in macroporous resin, lower alcohol elution and low temperature concentration into dry powder. The pharmacological effect of the Chinese medicine is also disclosed.
Description
Technical field
The present invention relates to a kind of treatment treating coronary heart disease and angina pectoris, being specifically related to the Chinese herbal medicine is the preparation that raw material is made through special process, the invention also discloses its pharmacological action.
Background technology
Angina pectoris is meant because coronary atherosclerosis or spasm cause myocardial ischemia, the caused angina pectoris of anoxia, accounts for 90% of patient with angina pectoris.At present, the anginal method of western medicine is mainly based on blood vessel dilating, reduction blood viscosity, antiplatelet aggregation, anticoagulation.The medicine of using is nitrate, nitrous acid ester, beta-blocker, calcium antagonist, thrombolytics etc., but because there is bigger toxic and side effects in it, unsuitable life-time service, and most drug is the treatment at symptom, do not have bigger effect for the progress of the course of disease.
Radix Salviae Miltiorrhizae is exsiccant of a Labiatae clary Radix Salviae Miltiorrhizae (Salvia miltiorrhiza Beg.).Aspect China treatment angina pectoris, the use history of existing nearly one thousand years is recorded in the Shennong's Herbal of the Eastern Han Dynasty the earliest, is listed as top gradely, has promoting the circulation of QI to relieve pain, mind tranquilizing and the heart calming, clearing away heat and cooling blood, effects such as blood circulation promoting and blood stasis dispelling.
Studies show that the active component of Radix Salviae Miltiorrhizae mainly contains two classes: a class is to be the fat-soluble effective site of representative with the TANSHINONES; Another kind of then is to be the water solublity effective site of representative with the salvianolic acid.Recent study thinks that aqueous soluble active constituent is the effective ingredient of blood circulation promoting and blood stasis dispelling.For example, salvianolic acid A has significant protective effect to the myocardial cell injury that ischemia-reperfusion causes, total salvianolic acid shows stronger ischemia resisting and pours into the arrhythmia effect again; Salvianolic acid A, salvianolic acid B and total salvianolic acid have protective effect to the brain injury that the mouse brain ischemia-reperfusion causes, can reduce MDA content in the cerebral tissue; The salvianolic acid anti thrombotic action; Salvianolic acid is to the protective effect of liver, kidney; Salvianolic acid has very strong antioxidation, can remove superoxide anion and release basic free radical, suppresses lipid peroxidation, or the like.(Du Guanhua etc., preclinical medicine and clinical, 2000,20 (5): 10～14).
Up to now, the extracting method at salvia-soluble position mostly is water and carries the back resin column of crossing, for example, extracting method (the Chemical Pharmaceutical Bulletin of the salvianolate of report such as Takashi Tanaka, 1989,37 (2), 340～344), in addition, (Planta Medica such as KojiHase, 1997,63,22～26), (Chinese patent CN1247855A such as Xu Yaming, in March, 2000 is open), Liu's equality (Chinese patent CN1270809A, in October, 2000 is open), ma Li Lian etc. (Chinese patent, application number 01142288.2, the calendar year 2001 applying date JIUYUE) also adopt similar method from Radix Salviae Miltiorrhizae, to extract phenolic acid compound.One of common defects of above method is to concentrate aqueous extract, because the temperature height when salvia-soluble position stability and processing and the length in processing time etc. have bigger relation, so generally take the mode of concentrating under reduced pressure, but good concentrating under reduced pressure equipment is comparatively expensive, as repeatedly concentrating under reduced pressure in the technology, can make process complications, cause the commercial production cost very high, seriously hinder the realization of its suitability for industrialized production.Another defective is that productive rate is lower, is generally 2～3%, and low productive rate has also limited these methods in industrial application.
The present invention adds acid for adjusting pH value after adopting the Radix Salviae Miltiorrhizae water extraction, and after the filtration, the separation and purification through resin reaches more than 70% its total phenolic content, makes preparation with proper supplementary material.Animal experiment shows that prevention and treatment angina pectoris are had the effect of highly significant.
Summary of the invention
The objective of the invention is to overcome above the deficiencies in the prior art, a kind of treatment of determined curative effect is provided and prevents coronary heart disease, anginal medicine.
Another object of the present invention provides the pharmacological action of this medicine.
The present invention is implemented by following scheme.
A) get red rooted salvia after the pulverizing, add hot water extraction, filter merging filtrate;
B) filtrate is regulated pH value, discards precipitation, gets supernatant;
C) supernatant is removed impurity through macroporous resin adsorption and water;
D) with lower alcohol eluting macroporous resin, collect eluent;
E) concentrate eluant becomes dry powder.
Wherein: in the step a), the water extraction number of times is twice, and for the first time amount of water is 6～8 times of medical material amount, and extraction time is 1～3 hour, and amount of water is 4～6 times of medical material amount for the second time, and extraction time is 1～2 hour; Wherein optimal conditions is 7 times of medical material amount for amount of water for the first time, and extraction time is 2 hours, and amount of water is 5 times of medical material amount for the second time, and extraction time is 1.5 hours.
In the step b), regulate filtrate pH value to 1～5, regulating the used acid of filtrate pH value is mineral acid; Wherein optimum condition is that pH value is adjusted to 1～4, and optimal pH is 2, and regulating the used acid of filtrate pH value is hydrochloric acid.
In the step d), be adsorbed in the aqueous C of effective ingredient on the macroporous resin
1～C
5The lower alcohol eluting, eluting concentration is 30～80%; C wherein
1～C
5Lower alcohol be respectively methanol, ethanol, propanol, isopropyl alcohol, n-butyl alcohol, isobutanol, amylalcohol, isoamyl alcohol, be preferably ethanol; Preferred concentration is 50～80%, and optium concentration is 70%.
In the step e), the temperature of concentrate eluant is below 60 ℃, owing to be the easy oxidation Decomposition of salvia-soluble position high temperature of representative with the liposoluble ingredient, so select that this temperature concentrates, drying, not influential to its effective ingredient, actual effect is satisfactory.
The salvia-soluble effective part extract that adopts the inventive method to make can be made the dosage form on any pharmaceutics, also can cooperate other drug or component to make preparation together and use.
The present invention compared with prior art has following advantage:
1. technology is simple and direct.Radix Salviae Miltiorrhizae of the present invention adopts hot water extraction, behind acid for adjusting pH value, filters, and filtrate is directly gone up macroporous resin column and separated.Wherein with the method for acid for adjusting pH value replaced of the prior artly concentrating, precipitate with ethanol etc. some seem simple and on commercial production actual comparatively complicated process, especially save the concentrating of aqueous solution, make process equipment more simple.Simultaneously, regulate pH value before the upper prop, can also remove a lot of impurity, guaranteed that the content of salvianolic acid B is not less than 60% in the dry powder.In addition, as can be seen: Fig. 1 (adopting the Comparative Examples method to obtain the high performance liquid chromatogram collection of illustrative plates) and figure from accompanying drawing
2 (adopting the inventive method to obtain the high performance liquid chromatogram collection of illustrative plates) are compared, the impurity peaks D in its product, and Fig. 1 is significantly less than Fig. 2; In addition, the ratio of peak A and B has taken place to change significantly; Peak C wherein is the index components salvianolic acid B, compares two kinds of methods as can be seen, and the inventive method is apparently higher than the Comparative Examples method.
2. loss of effective components is few.The present invention has avoided because of unfavorable factor such as temperature height, time length in the concentration process influence of salvia-soluble effective site stability having been reduced loss of active ingredients.
3. productive rate height, and total phenolic content height.From Comparative Examples and embodiment 1～5 as can be seen, the finished product of prior art (Radix Salviae Miltiorrhizae total phenolic acids dry powder) yield is generally 3.6% of crude drug amount, and the content of total phenolic acid is 72.1% in the finished product, and salvianolic acid content is 58.9%; And adopt product yield that the inventive method obtains generally between 4.59～4.80%, and the content of total phenolic acid is 74.7～76.2% in the finished product, and salvianolic acid content is 62.9～65.3%, and apparently higher than the method that prior art adopted, impurity is few, the quality height.
4. cost is low.Required process equipments (the particularly concentrator of aqueous solution) such as the present invention concentrates owing to saving repeatedly, precipitate with ethanol, the industrial equipment cost is lower; Radix Salviae Miltiorrhizae total phenolic acids productive rate height of the present invention, and the content of Radix Salviae Miltiorrhizae total phenolic acids content and prior art is close or be higher than the content of prior art, promptly same crude drug amount can be produced the product that more multimass is identical or quality is higher, the low and high efficiency of cost.
5. animal experiment study has also illustrated the beneficial effect according to the salvia-soluble effective site of method preparation of the present invention.
Experimental example
Below by zoopery, observe the influence of the salvia-soluble effective site that obtains by this method to the anesthetized dog myocardial infarct size, beneficial effect of the present invention is described.
1. test material
(1) medicine: be subjected to reagent, adopt the prepared salvia-soluble effective site of method of the present invention.
(2) Radix Salviae Miltiorrhizae Tabellae, Chinese medicine three factories in Shanghai produce, lot number: 980605.
(3) 0.9% sodium chloride injections, the Beijing Double-Crane Pharmaceutical Co., Ltd produces, lot number: 9900210222.
2. method
Animal via pentobarbital sodium (30m/kg) intravenous anesthesia, tracheal intubation, connect SC-2 type electric pulmotor: left side the 4th intercostal is opened breast, exposes heart, cuts off pericardium, makees the pericardium bed; Separate LCA, place the electromagnetic flowmeter probe, measure the heart coronary flow; Separate the anterior descending coronary stage casing, threading causes the acute experiment myocardial infarction and ischemia model in order to ligation; Seam is put the fixed epicardial lead of multiple spot, connects polygraph, traces epicardial electrogram.Ligation arteria coronaria 15 minutes, carry out record, as control value before the administration, test medicine or normal saline through duodenum, 30 mapping point visceral pericardium electrographs of 15,30,45,60,90,120,180 minutes records behind medicine, raising greater than 2mV with the S-T section is criterion, and (S-T section total mv that raises counts ∑-ST) and myocardial ischemia scope (raise total points N-ST) of S-T section to the calculating myocardium degree of ischemia.
180 minutes records finish behind the medicine, take off heart, normal saline flushing immediately, weighing is heavy whole-heartedly, below the heart ligature, is parallel to coronary sulcus equably with 5 of ventricle part crosscuts, then, place nitro tetrazole orchid (N-BT) dye liquor, room temperature dyeing 15 minutes.The infarct (the non-dyeing of N-BT district) of measuring every myocardium bilateral with color pathological image analysis system (MPIAS-500) and non-infarct (N-DT dye district) calculate area, the ventricle gross area and the infarct gross area of every cardiac muscle.Calculating infarct accounts for ventricle and accounts for dirty whole-heartedly percentage ratio.Experimental result is carried out statistical procedures, judges its significance with the t check.
3. result
Influence to dog acute myocardial infarction scope
The results are shown in following table, quantitative tissue is learned the N-BT staining and is shown myocardial infarct size, and normal saline control animals myocardial infarction area accounts for 8.48 ± 0.48% and 20.66 ± 1.99% of heart and ventricle respectively; Be subjected to reagent treated animal myocardial infarction zone to account for 7.71 ± 0.81% of heart 2.60 ± 0.60% and ventricle, with the normal saline matched group difference (all P＜0.001) of highly significant is arranged more all, be subjected to reagent treated animal myocardial infarction degree to be lower than the Radix Salviae Miltiorrhizae Tabellae group simultaneously, have significant difference (P＜0.01).
Each administration group is to the influence (n=5) of dog acute myocardial infarction scope
Group dosage/kg heart area mm
2Ventricle area mm
2Infarct area mm
2Infarct/cardiac infarction district/ventricle
Normal saline 3ml 13494.2 ± 1091.4 5228.6 ± 646.0 1110.05 ± 218.01 8.48 ± 0.48 20.66 ± 1.99
Radix Salviae Miltiorrhizae Tabellae 2g 12792.9 ± 2272.0 5123.7 ± 585.1 429.2 ± 90.9
* *3.17 ± 0.88
* *9.05 ± 2.18
* *
Be subjected to reagent 2g 16328.3 ± 6037.6 4983.1 ± 529.5 367.2 ± 55.8
* *2.60 ± 0.60
* * ▲ ▲7.71 ± 0.81
* * ▲ ▲
Annotate: compare with matched group: * P＜0.05; * P＜0.01; * * P＜0.001; Contrast with the Radix Salviae Miltiorrhizae Tabellae group:
▲ ▲P＜0.01.
Description of drawings
Fig. 1 is the high performance liquid chromatogram spectrogram of the Radix Salviae Miltiorrhizae extract that adopts the Comparative Examples method and obtain;
Fig. 2 is the high performance liquid chromatogram spectrogram of the Radix Salviae Miltiorrhizae extract that adopts the embodiment of the invention two methods and obtain.
The specific embodiment
The present invention is further illustrated below in conjunction with Comparative Examples and embodiment, and following this embodiment only is used to the present invention is described and to the present invention without limits.
Comparative Examples
By the patent application document (Chinese patent, application number 01142288.2, the calendar year 2001 applying date JIUYUE) method prepare Radix Salviae Miltiorrhizae total phenolic acids
Radix Salviae Miltiorrhizae 500g is ground into coarse powder, adds deionized water 100 ℃ of heating extraction 2 times.Add for the first time the water of 7 times of amounts, heated 2 hours; Add for the second time 5 times of water gaging heating 1 hour.Extracting solution is evaporated to 500ml at 50 ℃, cooling, and the gained concentrated solution is by macroporous adsorbent resin (D101 type), and being washed till effluent with deionized water does not have alphanaphthol reaction, continues to get eluent 3000ml with 50% ethanol elution.Eluent gets dry powder 18.0g, i.e. salvia-soluble extractive part through concentrating under reduced pressure.Product yield 3.6% of the dose of making a living, its finished product contains total phenolic acid 72.1% after testing, and salvianolic acid B is 58.9%.
The detection method of Radix Salviae Miltiorrhizae total phenolic acids and salvianolic acid B: by the patent application document (Chinese patent, application number 01142288.2, the calendar year 2001 applying date JIUYUE) method measure.
(1) salvianolic acid B: measure with the HPLC method, detect wavelength 288nm, the standard substance salvianolic acid B provides purity 98.0% by sky, Tianjin Shi Li group modern Chinese medicine institute.
(2) Radix Salviae Miltiorrhizae total phenolic acids: content=F (A-B)+B
Wherein: A is that spectrophotometry is total phenolic content that contrast is calculated with the salvianolic acid B
B is the content of danshinolic acid B of high effective liquid chromatography for measuring
F is a correction factor 0.626
Embodiment one
Radix Salviae Miltiorrhizae 500g is ground into coarse powder, adds deionized water heating extraction 2 times under 100 ℃ of slight boiling conditions.For the first time add 6 times of water, heated 1 hour: add 4 times of water gagings for the second time and heated respectively 1 hour.After merge extractive liquid, is 1 with 10% hydrochloric acid adjust pH, filter, collect filtrate, last macroporous adsorbent resin (D101 type), continues to use 80% methanol-eluted fractions to neutral with deionized water rinsing, treats that colour band gets off promptly to collect this colour band.55 ℃ of concentrating under reduced pressure become dry powder, salvia-soluble effective site 24.05g, product yield 4.80% of the dose of making a living.By the patent application document (Chinese patent, application number 01142288.2, the calendar year 2001 applying date JIUYUE) method measure, finished product contains total phenolic acid 75.9%, salvianolic acid B is 64.9%.
Embodiment two
Radix Salviae Miltiorrhizae 500g is ground into coarse powder, adds deionized water 80 ℃ of heating extraction 2 times.7 amount times water heated 2 hours for the first time; For the second time adding 5 times of water gagings heated respectively 1.5 hours.After extracting solution is 2 with 10% hydrochloric acid adjust pH, filter, collect filtrate and go up macroporous adsorbent resin (D101 type), to neutral, continue to use 70% ethanol elution, treat that colour band gets off promptly to collect this colour band with deionized water rinsing.50 ℃ of concentrating under reduced pressure become dry powder, salvia-soluble effective site 23.75g, product yield 4.75% of the dose of making a living.By the patent application document (Chinese patent, application number 01142288.2, the calendar year 2001 applying date JIUYUE) method measure, finished product contains total phenolic acid 76.2%, salvianolic acid B is 65.3%.
Embodiment three
Radix Salviae Miltiorrhizae 500g is ground into coarse powder, adds deionized water heating extraction 2 times under 100 ℃ of slight boiling conditions.Add for the first time 8 amount times water, heated 3 hours; For the second time respectively adding 6 times of water gagings heated respectively 2 hours.After extracting solution is 3 with 10% sulphuric acid adjust pH, filter, collect filtrate and go up macroporous adsorbent resin (AB-8 type), to neutral, continue to treat that with 60% propanol eluting colour band gets off promptly to collect this colour band with deionized water rinsing.45 ℃ of concentrating under reduced pressure become dry powder, salvia-soluble effective site 22.95g, product yield 4.59% of the dose of making a living.By the patent application document (Chinese patent, application number 01142288.2, the calendar year 2001 applying date JIUYUE) method measure, finished product contains total phenolic acid 74.7%, salvianolic acid B is 64.2%.
Embodiment four
Radix Salviae Miltiorrhizae 500g is ground into coarse powder, adds deionized water heating extraction 2 times under 100 ℃ of slight boiling conditions.Add for the first time 7.5 amount times water, heated 2.5 hours; For the second time respectively adding 5.5 times of water gagings heated respectively 2 hours.After extracting solution is 4 with 10% hydrochloric acid adjust pH, filter, collect filtrate and go up macroporous adsorbent resin (AB-8 type), to neutral, continue to treat that with 50% butanols eluting colour band gets off promptly to collect this colour band with deionized water rinsing.40 ℃ of concentrating under reduced pressure become dry powder, salvia-soluble effective site 23.25g, product yield 4.65% of the dose of making a living.By the patent application document (Chinese patent, application number 01142288.2, the calendar year 2001 applying date JIUYUE) method measure, finished product contains total phenolic acid 75.1%, salvianolic acid B is 63.8%.
Embodiment five
Radix Salviae Miltiorrhizae 500g is ground into coarse powder, adds deionized water heating extraction 2 times under 100 ℃ of slight boiling conditions.Add for the first time 7.5 amount times water, heated 2.5 hours; For the second time respectively adding 5.5 times of water gagings heated respectively 2 hours.After extracting solution is 5 with 10% hydrochloric acid adjust pH, filter, collect filtrate and go up macroporous adsorbent resin (AB-8 type), to neutral, continue to treat that with 30% amylalcohol eluting colour band gets off promptly to collect this colour band with deionized water rinsing.40 ℃ of concentrating under reduced pressure become dry powder, salvia-soluble effective site 23.35g, product yield 4.67% of the dose of making a living.By the patent application document (Chinese patent, application number 01142288.2, the calendar year 2001 applying date JIUYUE) method measure, finished product contains total phenolic acid 75.0%, salvianolic acid B is 62.9%.
Claims (19)
1. the extracting method of an active component of red sage root is characterized in that comprising:
A. get the red rooted salvia after the pulverizing, add hot water extraction, filter merging filtrate;
B. filtrate is regulated pH value, discards precipitation, gets supernatant;
C. supernatant is removed impurity through macroporous resin adsorption and water;
D. use lower alcohol eluting macroporous resin, collect eluent;
E. concentrate eluant becomes dry powder.
2. preparation method according to claim 1 is characterized in that water extraction twice among the step a, and for the first time amount of water is 6～8 times of medical material amount, and extraction time is 1～3 hour, and amount of water is 4～6 times of medical material amount for the second time, and extraction time is 1～2 hour.
3. preparation method according to claim 1 is characterized in that water extraction twice among the step a, and for the first time amount of water is 7 times of medical material amount, and extraction time is 2 hours, and amount of water is 5 times of medical material amount for the second time, and extraction time is 1.5 hours.
4. preparation method according to claim 1 is characterized in that regulating among the step b filtrate pH value to 1～5.
5. preparation method according to claim 1 is characterized in that regulating among the step b filtrate pH value to 1～4.
6. preparation method according to claim 1 is characterized in that regulating among the step b filtrate pH value to 2.
7. preparation method according to claim 1 is characterized in that regulating the used acid of filtrate pH value among the step b is mineral acid.
8. preparation method according to claim 1 is characterized in that regulating the used acid of filtrate pH value among the step b is hydrochloric acid.
9. preparation method according to claim 1 is characterized in that the macroporous resin among the step c is a styrene type porous adsorbent resin.
10. preparation method according to claim 1 is characterized in that being adsorbed in the steps d the aqueous C of effective ingredient on the macroporous resin
1～C
5The lower alcohol eluting.
11. preparation method according to claim 10 is characterized in that being adsorbed in the steps d the aqueous C of effective ingredient on the macroporous resin
1～C
5The lower alcohol eluting, eluting concentration is 30～80%.
12. preparation method according to claim 10 is characterized in that being adsorbed in the steps d the aqueous C of effective ingredient on the macroporous resin
1～C
5The lower alcohol eluting, eluting concentration is 50～80%.
13. preparation method according to claim 10 is characterized in that being adsorbed in the steps d the aqueous ethanol of effective ingredient on the macroporous resin, eluting concentration is 70%.
14. preparation method according to claim 1, the temperature that it is characterized in that concentrate eluant among the step e is below 60 ℃.
15. the extracting method of a kind of active component of red sage root according to claim 1, its feature comprises:
A. get the red rooted salvia after the pulverizing, extracting in water twice adds 6 times of water for the first time, heat 1 hour: add 4 times of water gagings for the second time and heated respectively 1 hour, add hot water extraction, filtration discards precipitation, gets supernatant;
B. adopt 10% hydrochloric acid that above-mentioned filtrate pH value is transferred to 1.0, filter, collect filtrate,
C. supernatant is removed impurity through macroporous resin adsorption and water;
D. use 80% methanol-eluted fractions macroporous resin, collect eluent;
E.55 ℃ following concentrating under reduced pressure eluent becomes dry powder.
16. the extracting method of a kind of active component of red sage root according to claim 1, its feature comprises:
A. get the red rooted salvia after the pulverizing, extracting in water twice adds 7 times of water for the first time, heat 2 hours: add 5 times of water gagings for the second time and heated respectively 1.5 hours, add hot water extraction, filtration discards precipitation, gets supernatant;
B. adopt 10% hydrochloric acid that above-mentioned filtrate pH value is transferred to 2.0, filter, collect filtrate,
C. supernatant is removed impurity through macroporous resin adsorption and water;
D. use 70% ethanol elution macroporous resin, collect eluent;
E.50 ℃ following concentrating under reduced pressure eluent becomes dry powder.
17. the extracting method of a kind of active component of red sage root according to claim 1, its feature comprises:
A. get the red rooted salvia after the pulverizing, extracting in water twice adds 8 times of water for the first time, heat 3 hours: add 6 times of water gagings for the second time and heated respectively 2 hours, add hot water extraction, filtration discards precipitation, gets supernatant;
B. adopt 10% hydrochloric acid that above-mentioned filtrate pH value is transferred to 3.0, filter, collect filtrate,
C. supernatant is removed impurity through macroporous resin adsorption and water;
D. use 60% propanol eluting macroporous resin, collect eluent;
E.45 ℃ following concentrating under reduced pressure eluent becomes dry powder.
18. a treatment treating coronary heart disease and angina pectoris is characterized in that containing the prepared active component of red sage root of any method of claim 1～17.
19. the application of active component of red sage root in the preparation medicine according to the described either party's method preparation of claim 1～17 is characterized in that said medicine has the effect that improves acute myocardial ischemia and myocardial infarction; Effect with the damage that alleviates myocardial ischemia-reperfusion; Have coronary blood flow increasing, blood vessel dilating, increase venous oxygen content reduce the myocardial oxygen consumption index, improve the effect of myocardial ischemia; Effect with anticoagulant; Has the thrombotic effect of vitro inhibition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031308619A CN100502901C (en) | 2003-05-20 | 2003-05-20 | Extraction method for effective parts of salvia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031308619A CN100502901C (en) | 2003-05-20 | 2003-05-20 | Extraction method for effective parts of salvia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1548130A true CN1548130A (en) | 2004-11-24 |
| CN100502901C CN100502901C (en) | 2009-06-24 |
Family
ID=34322694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031308619A Expired - Lifetime CN100502901C (en) | 2003-05-20 | 2003-05-20 | Extraction method for effective parts of salvia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100502901C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1981818B (en) * | 2005-12-14 | 2010-12-15 | 天津天士力制药股份有限公司 | Chinese-medicinal composition, preparation and use for treating cardiovascular diseases |
| CN101434534B (en) * | 2007-11-12 | 2013-04-03 | 北京环京弘方生物科技有限公司 | Preparation of salvianic acid A sodium pure product |
| CN103505613A (en) * | 2012-06-28 | 2014-01-15 | 天津天狮生物发展有限公司 | Traditional Chinese medicine composition containing fatty acid and preparation method of composition |
-
2003
- 2003-05-20 CN CNB031308619A patent/CN100502901C/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1981818B (en) * | 2005-12-14 | 2010-12-15 | 天津天士力制药股份有限公司 | Chinese-medicinal composition, preparation and use for treating cardiovascular diseases |
| CN101434534B (en) * | 2007-11-12 | 2013-04-03 | 北京环京弘方生物科技有限公司 | Preparation of salvianic acid A sodium pure product |
| CN103505613A (en) * | 2012-06-28 | 2014-01-15 | 天津天狮生物发展有限公司 | Traditional Chinese medicine composition containing fatty acid and preparation method of composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100502901C (en) | 2009-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101073599A (en) | Total tanshinone and total phenolic acid extract in red-rooted salvia root and its production | |
| CN1202103C (en) | Preparation method of red sageroot total phenolic acid and its use | |
| CN100345558C (en) | Extract product of general flavone of kudzuvine root, preparation method and application | |
| CN100439319C (en) | Method for preparing salviol acid A | |
| CN103450296A (en) | Method for rapidly preparing forsythin from forsythia suspense leaves | |
| CN1229324C (en) | Extraction process of tanshin general phenolic acid and its prepn and use | |
| CN100502901C (en) | Extraction method for effective parts of salvia | |
| CN1733054A (en) | Dogwood fruit extract and its preparation process | |
| CN102100737B (en) | Medicinal composition containing general ginsenoside and total salvianolic acid and preparation method thereof | |
| CN103381200A (en) | White mulberry root-bark total alkaloid extract and preparation and application thereof | |
| CN102085226B (en) | Japanese common goldthread extract and its extraction process | |
| CN101310739B (en) | Cassia Tuckahoe composition and preparation method thereof | |
| CN1282468C (en) | Chinese medicine soft capsule Naodesheng and its preparing method | |
| CN1590383A (en) | Rod sage root extract and making method of its preparation | |
| CN1468860A (en) | Manyprickle acanthopanax general saponin extractive and its medicinal composition | |
| CN1081922C (en) | Medicinal composition containing ginsenoside Re, preparation and usage thereof | |
| CN113384641A (en) | Extraction and purification method of effective part of small red garlic for treating coronary heart disease, product and application thereof | |
| CN101077364A (en) | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method | |
| CN100518802C (en) | Extraction of effective parts for Danshen root and rhizoma chuanxiong | |
| CN1887309B (en) | Extraction of effective red sage components for preventing and treating osteoporosis and depression | |
| CN1903251A (en) | Shuangshen phenol glucoside injection, prepn. method and use thereof | |
| CN1817356A (en) | Production of vermilion injection for treating cardiovascular disease | |
| CN1733069A (en) | Oral cavity spray containing two effective parts of compound red sage root formula and its preparation process | |
| CN1695676A (en) | Method for preparing powder of red sage root with high content in use for administration through vein | |
| CN1557403A (en) | Medicine for treating angiocardiopathy and cerebrovascular disease and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Tianjin Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Tianjin Patentee before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Tianjin Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Tianjin Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CX01 | Expiry of patent term |
Granted publication date: 20090624 |
|
| CX01 | Expiry of patent term |